title: Haemorrhagic gastritis and bleeding following rofecoxib administration.
authors.forename: M
authors.initials: M
authors.lastname: Tuccori
authors.forename: G
authors.initials: G
authors.lastname: Martini
authors.forename: S E
authors.initials: SE
authors.lastname: Giustini
authors.forename: A
authors.initials: A
authors.lastname: Salvetti
authors.forename: C
authors.initials: C
authors.lastname: Blandizzi
authors.forename: M
authors.initials: M
authors.lastname: Del Tacca
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D005773:Gastroscopy; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy; D013450:Sulfones / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; D064747:Lansoprazole; C116926:rofecoxib; D009853:Omeprazole